Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review.
Temozolomide chemotherapy has become part of the therapy used to treat glioblastoma multiforme and refractory anaplastic astrocytoma. Temozolomide frequently produces profound lymphopenia. We report 2 cases of cytomegalovirus disease that occurred in patients receiving temozolomide therapy and review 4 additional cases reported in the literature. Narrow monitoring with cytomegalovirus antigenemia assay should be considered for recommendation.
Meije
Yolanda
Y
Infectious Diseases Unit, Hospital Universitario 12 de Octubre, Madrid, Spain. yolandameije@gmail.com
Lizasoain
Manuel
M
García-Reyne
Ana
A
Martínez
Pilar
P
Rodríguez
Virginia
V
López-Medrano
Francisco
F
Juan
Rafael San
RS
Lalueza
Antonio
A
Aguado
José María
JM
D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000150:complications / Q000188:drug therapy; D003586:Cytomegalovirus Infections / Q000150:complications* / Q000453:epidemiology; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005909:Glioblastoma / Q000150:complications / Q000188:drug therapy; D006801:Humans; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000150:complications; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide